Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 16/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.53 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28663748 | 0.91 | STAT3 (0.55) | STAT3MEN1MAPTKMT2APOLB | |
| SCHEMBL31006406 | 0.89 | STAT3 (0.55) | STAT3MEN1MAPTKMT2APOLB | |
| SCHEMBL2135809 | 0.89 | STAT3 (0.52) | STAT3MEN1MAPTKMT2APOLB | |
| SCHEMBL2135813 | 0.89 | STAT3 (0.52) | STAT3MEN1MAPTKMT2APOLB | |
| SCHEMBL29629350 | 0.88 | POLB (0.49) | STAT3MEN1MAPTKMT2APOLB | |
| SCHEMBL29391273 | 0.88 | POLB (0.49) | STAT3MEN1MAPTKMT2APOLB | |
| SCHEMBL29425864 | 0.87 | STAT3 (0.64) | STAT3MAPT | |
| SCHEMBL29425794 | 0.86 | STAT3 (0.57) | STAT3MEN1MAPTKMT2APOLB | |
| SCHEMBL29425822 | 0.86 | POLB (0.47) | STAT3MEN1MAPTKMT2APOLB | |
| Secologanin SCHEMBL21358657 | 0.84 | POLB (0.43) | STAT3MEN1MAPTKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 411 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4379068-B1 | IRIDOID OR SECO-IRIDOID DERIVATIVES AND THEIR USE IN A TANNING PROCESS | INSTITUT NAT DES SCIENCES APPLIQUEES DE ROUEN (FR) | 2025-06-04 | — | — | EP | claimed |
| EP-4526426-A2 | METHODS FOR PRODUCING MONOTERPENE INDOLE ALKALOIDS | Danmarks Tekniske Universitet (DK) | 2025-03-26 | — | — | EP | claimed |
| EP-4520348-A1 | CARBON CHAIN SUBSTANCE FOR REGULATING TRANSMEMBRANE TRANSPORT AND FLUIDITY OF CELL MEMBRANES, AND PREPARATION AND USE THEREOF | Sunforest (Beijing) Biopharma Ltd (CN) | 2025-03-12 | — | — | EP | claimed |
| WO-2024168348-A1 | PRODUCTION OF MONOTERPENE INDOLE ALKALOID COMPOUNDS IN A HETEROLOGOUS HOST | TRYPTAGENIX, INC. (US) | 2024-08-15 | — | — | WO | claimed |
| US-20240254533-A1 | METHODS FOR PRODUCING TRYPTAMINE DERIVATIVES | OCTARINE BIO APS (DK) | 2024-08-01 | — | — | US | claimed |
| EP-4379068-A1 | IRIDOID OR SECO-IRIDOID DERIVATIVES AND THEIR USE IN A TANNING PROCESS | Institut National Des Sciences Appliquées De Rouen (FR) | 2024-06-05 | — | — | EP | claimed |
| EP-4347856-A2 | METHODS FOR PRODUCING TRYPTAMINE DERIVATIVES | Octarine Bio ApS (DK) | 2024-04-10 | — | — | EP | claimed |
| US-20240017234-A1 | IMPROVED MICROCAPSULES AND METHOD FOR THE PRODUCTION AND USE THEREOF | Follman GmbH & Co. KG (DE) | 2024-01-18 | — | — | US | claimed |
| WO-2023222879-A2 | METHODS FOR PRODUCING MONOTERPENE INDOLE ALKALOIDS | DANMARKS TEKNISKE UNIVERSITET (DK) | 2023-11-23 | — | — | WO | claimed |
| CN-115792070-A | Method for measuring content of iridoid component in honeysuckle oral liquid | 真奥金银花药业有限公司 | 2023-03-14 | — | — | CN | claimed |
| EP-2001877-A1 | METHOD FOR EXTRACTING TARGET ALKALOID USING AN IONIC LIQUID AS EXTRACTING SOLVENT | Bioniqs Limited (GB) | 2008-12-17 | — | — | EP | claimed |
| WO-2008050916-A1 | OLEANANE TRITERPENE SAPONIN COMPOUNDS WHICH ARE EFFECTIVE ON TREATMENT OF DEMENTIA AND MILD COGNITIVE IMPAIRMENT(MCI), AND IMPROVEMENT OF COGNITIVE FUNCTION | SK CHEMICALS CO., LTD. (KR) | 2008-05-02 | — | — | WO | claimed |
| WO-2007146841-A2 | COLLAGEN CROSS-LINKING AGENTS ON DENTAL RESTORATIVE TREATMENT AND PREVENTIVE DENTISTRY | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-12-21 | — | — | WO | claimed |
| WO-2007110637-A1 | METHOD FOR EXTRACTING TARGET ALKALOID USING AN IONIC LIQUID AS EXTRACTING SOLVENT | BIONIQS LIMITED (GB) | 2007-10-04 | — | — | WO | claimed |
| EP-1548006-B1 | Synthesis of tetraazapentamethine derivatives, keratin fibers dyeing process which uses such synthesis | OREAL (FR) | 2007-09-05 | — | — | EP | claimed |
| US-20050198744-A1 | Applying 2-[5-(N-methyl-2-pyridinylidene)-1-formazano]-N-methylpyridinium chloride and an oxidizing agent, developing the desired coloration | L'OREAL S.A. (FR) | 2005-09-15 | — | — | US | claimed |
| EP-1548006-A1 | Synthesis of tetraazapentamethine derivatives, keratin fibers dyeing process which uses such synthesis | L'OREAL (FR) | 2005-06-29 | — | — | EP | claimed |
| WO-2000042200-A1 | STRICTOSIDINE GLUCOSIDASE FROM CATHARANTHUS ROSEUS AND ITS USE IN ALKALOID PRODUCTION | UNIVERSITEIT LEIDEN (NL) | 2000-07-20 | — | — | WO | claimed |
| EP-0156267-B1 | METHOD FOR THE PREPARATION OF STRICTOZIDIN | GYOGYNÖVENY KUTATO INTEZET (HU) | 1989-08-30 | — | — | EP | claimed |
| EP-0156267-A2 | Method for the preparation of strictozidin | GYOGYNÖVENY KUTATO INTEZET (HU) | 1985-10-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050198744-A1 | Applying 2-[5-(N-methyl-2-pyridinylidene)-1-formazano]-N-methylpyridinium chloride and an oxidizing agent, developing the desired coloration | KRT18, TPM4, AZI2 | STAT3 3542/4885MEN1 3246/4885MAPT 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.